Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Telix Pharmaceuticals Limited

Comparative cost analysis of Corcept and Telix from 2014-2023.

__timestampCorcept Therapeutics IncorporatedTelix Pharmaceuticals Limited
Wednesday, January 1, 201488200022622695
Thursday, January 1, 2015136100024863028
Friday, January 1, 2016205800021351001
Sunday, January 1, 2017355400053837297
Monday, January 1, 2018521500016080096
Tuesday, January 1, 2019550400018525736
Wednesday, January 1, 202055820002024000
Friday, January 1, 202152810002548000
Saturday, January 1, 2022538500061556000
Sunday, January 1, 20236481000188157000
Loading chart...

Data in motion

Cost of Revenue Trends: Corcept Therapeutics vs. Telix Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Corcept Therapeutics Incorporated and Telix Pharmaceuticals Limited from 2014 to 2023. Over this period, Corcept Therapeutics saw a steady increase in its cost of revenue, peaking at approximately $6.5 million in 2023, marking a growth of over 630% from 2014. Meanwhile, Telix Pharmaceuticals experienced a more volatile trajectory, with a dramatic surge in 2023, reaching nearly $188 million, a staggering increase of over 730% from its 2014 figures. This stark contrast highlights the differing operational scales and market strategies of these two companies. Investors should note the significant growth in Telix's cost of revenue, which may indicate aggressive expansion or increased production costs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025